'Two-Step Authentication' for Optimal Prostate Cancer Risk Determination: An "Extracellular Vesicle"-Based Liquid Biopsy Followed by Multi-Parametric MRI.

用于最佳前列腺癌风险确定的“两步验证”：基于“细胞外囊泡”的液体活检，随后进行多参数 MRI。

• 批准号: 462401
• 负责人: Leong Hon Sing
• 金额: $ 119.26万
• 依托单位: Sunnybrook Research Institute (Toronto, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-03-01 至 2027-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=462401&lang=en
• 关键词: "Liquid Biopsy"; Benign Prostatic Hyperplasia; Extracellular Vesicles; Gleason Group Score; Multi-Parametric Magnetic Resonance; Pi-Rads V2; Prostate Cancer; Prostate Needle Biopsy; Radiology; Risk Stratification

Early detection and diagnosis of prostate cancer still needs significant improvement. Too many men are erroneously submitted to an invasive biopsy procedure that will reveal no evidence of cancer. More than half of biopsy procedures done in Canada and the

前列腺癌的早期检测和诊断仍需要显着改进。太多的男性被错误地接受了侵入性活检程序，而该程序不会发现癌症的证据。超过一半的活检程序在加拿大和美国进行